Results 231 to 240 of about 257,086 (309)
FAK signaling drives chemoresistance and tumor evolution in pancreatic ductal adenocarcinoma. The FAK inhibitor IN10018 restores gemcitabine sensitivity by inducing SLC7A11‐mediated ferroptosis through the PI3K‐Akt pathway and remodeling the tumor microenvironment, reducing mesenchymal components while enhancing CD8+ T‐cell infiltration in preclinical ...
Yingjin Wang +11 more
wiley +1 more source
Intraoperative Cytology of Ovarian Neoplasms with an Attempt to Grade Epithelial Tumors.
Bohara S +5 more
europepmc +1 more source
This study identifies a FOSL2‐driven positive feedback loop that amplifies FSH/FSHR signaling. During FSH‐dependent follicle maturation, FSH induces Fosl2 expression via the cAMP‐PKA‐CREB cascade. FOSL2 in turn binds the promoters of Fshr and estrogen‐biosynthesis genes to enhance their transcription, thereby increasing Fshr mRNA level and amplifying ...
Hongru Shi +13 more
wiley +1 more source
Selenium‐Based Nanoplatforms: An Emerging Theranostic Paradigm for Gynecological Cancers
This reivew summarizes Selenium as a multifunctional anticancer regulator in gynecological cancers. It reduces tumor risk, enhances therapeutic efficacy, and reduces treatment toxicity. Selenium also overcomes chemoraditherapy resistance, improving overall treatment outcomes. ABSTRACT Gynecological cancers present significant therapeutic challenges due
Hejing Liu +9 more
wiley +1 more source
Childhood ovarian neoplasms in Ibadan, South-western Nigeria.
Ajani MA +4 more
europepmc +1 more source
The mammalian TGFβ interacts with ubiquitously expressed TGFBR1 and TGFBR2, and current TGFβ‐targeting agents are non‐cell‐selective. The cooperative interaction of the modular parasite TGFβ antagonist with multiple host (co‐)receptors empowers the design of TGM chimeras and bispecific antibodies that activate or inhibit TGFβ signaling in a cell ...
Maarten van Dinther +13 more
wiley +1 more source
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs +4 more
wiley +1 more source

